Eli Lilly Plans Increased Dealmaking Amid GLP-1 Drug Success

Eli Lilly is leveraging the strong performance of its GLP-1 drugs, Mounjaro and Zepbound, to fund acquisitions. The company reported significant sales growth for these products in Q1 2026 but faces risks due to their concentration in revenue and potential patent expiration.

By Reuben Gregg Brewer, The Motley Fool Thu, June 4, 2026 at 4:47 PM GMT+3 4 min read · Yahoo Finance · June 4, 2026, 13:47 UTC

Eli Lilly Plans Increased Dealmaking Amid GLP-1 Drug Success

Tickers: $LLY $NVO

Topics: acquisitions GLP-1 drugs patent risks sales growth

Read the full article at Yahoo Finance

More World news

Nvidia Appoints Colette Kress as Interim CEO Following Jensen Huang's Resignation CNBC · November 12, 2026, 16:59 UTC
Brookfield Corporation Reports Strong Third Quarter Earnings Growth and Increased Share Buybacks Motley Fool · November 12, 2026, 17:08 UTC
Franco-Nevada Reports Q3 2026 Revenue Growth Driven by Higher Gold and Oil Prices Motley Fool · November 12, 2026, 17:10 UTC
Stratasys Reports Q3 2026 Revenue Growth Driven by Aerospace and Defense Demand Motley Fool · November 12, 2026, 17:11 UTC
Jim Cramer Advises Profit-Taking Following Jensen Huang's Resignation at Nvidia CNBC · November 12, 2026, 16:59 UTC
LexisNexis Report Shows Elevated U.S. Auto Insurance Shopping Volumes in Q3 2026 PR Newswire · November 12, 2026, 17:12 UTC
Suburban Propane Partners Outlines $60M-$70M Capital Expenditures for Fiscal 2027 Seeking Alpha · November 12, 2026, 17:00 UTC
Nvidia, Supermicro, and Megaspeed Face U.S. Department of Justice Probes Seeking Alpha · November 12, 2026, 17:00 UTC
Starbucks Implements Quarterly Performance-Based Bonuses for Baristas Seeking Alpha · November 12, 2026, 17:03 UTC
Jim Cramer Analyzes Nvidia Leadership Transition and Recommends AMD, Constellation Brands, and Kimberly-Clark CNBC · November 12, 2026, 16:55 UTC